Infinity Bio develops a proprietary MIPSA platform for unbiased, high-resolution analysis of the antibody reactome to reveal immune targets across viruses, human proteins, and allergens. Since founding in 2023 the company has built a 9,000 square-foot laboratory in Baltimore and developed core services including HuSIGHT™, VirSIGHT™, AllerSIGHT™, and MuSIGHT™. Its platform is capable of processing thousands of samples per week and serves academic, government, and biopharma customers. Infinity Bio recently acquired the assets of Serimmune, Inc., broadening its suite of antibody reactome services. The company plans to use investment proceeds to expand its commercial footprint, accelerate MIPSA development, and launch new immune profiling services. New MIPSA service offerings, including EnviroSIGHT™, are expected to launch in the second half of 2025.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2025